

Claims

- 1) Peptide variants of MUC1 within the VNTR (variable number of tandem repeats) domain comprising 20 aa which deviate at positions 9 and 18 and / or 19 from the well-known VNTR domain.
- 2) Peptide variants according to claim 1, characterized by the SEQ ID No. 2 sequence PAPGSTAPPAHGVTSAPESR (PAP20-ES).
- 3) Peptide variants according to claim 1, characterized by the SEQ ID No. 3 sequence PAPGSTAPAAHGVTSAPESR (PAP20-AES).
- 4) Immunogenic substances / reagents characterized by their content of at least one of the peptides specified under claims 1 to 3 or the SEQ ID No. 1 sequence PAPGSTAPAAHGVTSAPDTR (PAP20-A).
- 5) Antigenic substances / reagents characterized by their content of at least one of the peptides specified under claims 1 to 3 or the SEQ ID No. 1 sequence PAPGSTAPAAHGVTSAPDTR (PAP20-A).
- 6) Test kit for the determination of identity and incidence of DNA mutations within the VNTR domain, which contains at least one of the primer sequences corresponding to one of the peptides specified under claims 1 to 3 or the SEQ ID No. 1 sequence PAPGSTAPAAHGVTSAPDTR (PAP20-A).
- 7) Use of these peptides specified under claims 1 to 3 or the SEQ ID No. 1 sequence PAPGSTAPAAHGVTSAPDTR (PAP20-A) for the generation of cancerostatic remedies, especially for the generation of effective vaccines in a tumor therapeutic context.